Uveitis is
an inflammation of the iris, choroid, and ciliary body, which make up the
middle layer of tissue in the uvea of the eye wall. Uveitis is treated with a
variety of medications, including cycloplegic agents, anti-inflammatory,
antibacterial treatments, immunotherapy, targeted therapies, and others.
Anterior uveitis, middle uveitis, posterior uveitis, and panuveitis are all
kinds of uveitis. The most frequent type of uveitis is iritis, or anterior
uveitis, which is an inflammation of the iris.
Because of
the growing older population, the pervasiveness of uveitis, and accompanying
comorbidities, the Uveitis Treatment
landscape has changed dramatically. In addition, the launch of innovative
biologics, fast-track pipeline medications, and increased investment in
research & development for new drug discoveries are all propelling the Uveitis
Treatment Market forward.
Drivers of the Global Uveitis
Treatment Market
Over the
forecast period, the high prevalence of uveitis is expected to drive growth in
the worldwide Uveitis
Treatment Market. According to the study 'Epidemiology of
uveitis in urban Australia,' published in the journal Clinical and Experimental
Ophthalmology in April 2019, the incidence of uveitis was 21.54 per 100 000
person?years. The prevalence of the disease was 36.27 per 100 000 people at the
time.
Furthermore,
the rising prevalence of autoimmune illnesses is likely to boost market growth.
According to a research published in February 2019 in the journal Neurology by
the National MS Society, almost 1 million persons in the United States had
multiple sclerosis in 2017.
 |
| Uveitis Treatment Market |
Opportunities in the Global Uveitis
Treatment Market
Over the
projected period, promising compounds in clinical trials are expected to
provide lucrative growth prospects for participants in the worldwide uveitis
therapy market. Tarsius Pharma, a clinical-stage biopharmaceutical startup, for
example, concluded patient recruitment in its TRS01 Phase I/II trial in
patients with active anterior non-infectious uveitis in June 2020.
The high
prevalence of rheumatoid arthritis is also projected to boost market expansion.
According to the article "Global, regional, and national burden of
rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of
Disease study 2017," published in the Journal of the American College of
Rheumatology, "global, regional, and national burden of rheumatoid
arthritis 1990-2017: a systematic analysis of the Global Burden of Disease
study 2017,"
Key Developments in the Global
Uveitis Treatment Market
To extend
their product range, major market players are focusing on R&D of new goods.
For example, EyePoint Pharmaceuticals, Inc. released positive topline 36-month
follow-up data from the second Phase 3 trial of the YUTIQ (fluocinolone
acetonide intravitreal implant) 0.18 mg three-year micro-insert for the
treatment of glaucoma.
Comments
Post a Comment